Genetic Signatures (ASX:GSS) - Cotización, noticias y análisis

Resumen de acción GSS

Genetic Signatures Limited opera como empresa de diagnóstico molecular en Australia, Asia-Pacífico, Europa, Oriente Medio, Asia y América. Saber más

Análisis fundamental de GSS
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	6/6
Rendimiento pasado	0/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Cotiza un 84% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 98.62%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Competidores de Genetic Signatures Limited

Proteomics International Laboratories

ASX:PIQ

AU$89.1m

Trajan Group Holdings

ASX:TRJ

AU$155.3m

EZZ Life Science Holdings

ASX:EZZ

AU$127.5m

Cryosite

ASX:CTE

AU$43.0m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Genetic Signatures
Precios históricos de las acciones
Precio actual de la acción	AU$0.72
Máximo en las últimas 52 semanas	AU$0.85
Mínimo de 52 semanas	AU$0.38
Beta	0.054
1Cambio en 1 mes	12.11%
Variación en 3 meses	1.06%
Cambio de 1 año	44.95%
3Variación en 3 años	-42.37%
Variación en 5 años	-34.77%
Variación desde la OPV	47.94%

Noticias y actualizaciones recientes

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Rentabilidad de los accionistas

	GSS	AU Life Sciences	Mercado AU
7D	0.3%	-6.0%	1.5%
1Y	44.9%	11.8%	17.2%

Rentabilidad vs. Industria: GSS superó a la industria Australian Life Sciences, que obtuvo un rendimiento del 11.8% el año pasado.

Rentabilidad vs. Mercado: GSS superó al mercado Australian, que obtuvo un rendimiento del 17.2% el año pasado.

Volatilidad de los precios

Is GSS's price volatile compared to industry and market?
GSS volatility
GSS Average Weekly Movement	6.6%
Life Sciences Industry Average Movement	11.2%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: GSS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GSS (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	n/a	Allison Rossiter	www.geneticsignatures.com

Genetic Signatures Limited opera como empresa de diagnóstico molecular en Australia, Asia-Pacífico, Europa, Oriente Medio, Asia y América. La empresa ofrece bacterias entéricas, Enteroaggregative E.coli aggR y aaiC, virus entéricos, protozoos entéricos, protozoos entéricos extendidos, microsporidios entéricos, patógeno respiratorio, SARS-CoV-2, SARS-CoV-2 respiratorio plus, coronavirus, respiratorio atípico, tos ferina y PCP, parainfluenza 4, patógeno genital de ITS, organismos productores de betalactamasas y carbapenemasas de espectro extendido, meningitis vírica, flavivirus dengue alfavirus, flavivirus reflejo, dengue tipificación y alfavirus reflejo Kits de detección bajo el nombre EasyScreen. Genetic Signatures Limited se constituyó en 2001 y tiene su sede en Newtown, Australia.

Resumen de fundamentos de Genetic Signatures Limited

¿Cómo se comparan los beneficios e ingresos de Genetic Signatures con su capitalización de mercado?
Estadísticas fundamentales de GSS
Capitalización bursátil	AU$158.81m
Beneficios(TTM)	-AU$17.86m
Ingresos (TTM)	AU$13.77m

11.8x

Ratio precio-ventas (PS)

-9.1x

Ratio precio-beneficio (PE)

¿Está GSS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GSS
Ingresos	AU$13.77m
Coste de los ingresos	AU$7.91m
Beneficio bruto	AU$5.86m
Otros gastos	AU$23.72m
Beneficios	-AU$17.86m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.079
Margen bruto	42.53%
Margen de beneficio neto	-129.74%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GSS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GSS

Recompensas

Análisis de riesgos

Competidores de Genetic Signatures Limited

ASX:PIQ

AU$89.1m

ASX:TRJ

AU$155.3m

ASX:EZZ

AU$127.5m

ASX:CTE

AU$43.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Recent updates

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Rentabilidad de los accionistas